Kalaris Therapeutics (NASDAQ:KLRS) Upgraded by Piper Sandler to Hold Rating
Kalaris Therapeutics (NASDAQ:KLRS – Get Free Report) was upgraded by equities researchers at Piper Sandler to a “hold” rating in a research report issued on Wednesday, Marketbeat.com reports. The firm currently has a $3.00 price objective on the stock. Piper Sandler’s price objective suggests a potential upside of 5.63% from the company’s previous close. Separately, […]
More Stories
Bobby Lee’s Net Worth And His Journey To Success
One of the oldest comedians from the US, Bobby Lee, has spent around 30 years in the field of comedy,...
UK Sanctions Russia After Inquiry Holds Putin Responsible for 2018 Novichock Poisonings
By Guy Birchall The UK issued new sanctions on Russia on Dec. 4, after a public inquiry into the death...
Indiana House Passes New Congressional Map Favoring Republicans
By Arjun Singh The Indiana House of Representatives on Dec. 5 passed a bill that would revise the state’s maps...
Economists Forecast Stronger US Growth, Lingering Inflation in 2026
By Tom Ozimek The U.S. economy will grow faster next year than previously projected and inflationary pressures will tick down,...
Noem Says US Travel Ban to Expand to Over 30 Countries
By Aldgra Fredly Homeland Security Secretary Kristi Noem said on Dec. 4 that the Trump administration is looking to increase...
Supreme Court Will Hear Trump’s Birthright Citizenship Case
By Matthew Vadum The U.S. Supreme Court decided on Dec. 5 to review whether President Donald Trump’s executive order ending birthright...